Atossa Therapeutics, Inc.ATOSNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank77
3Y CAGR+24.0%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+24.0%/yr
Quarterly compound
Percentile
P77
Within normal range
vs 3Y Ago
1.9x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 17.28% |
| Q2 2025 | -21.82% |
| Q1 2025 | 15.49% |
| Q4 2024 | -48.44% |
| Q3 2024 | -4.83% |
| Q2 2024 | 3.55% |
| Q1 2024 | 15.67% |
| Q4 2023 | -43.47% |
| Q3 2023 | 13.03% |
| Q2 2023 | 36.41% |
| Q1 2023 | -55.25% |
| Q4 2022 | 16.40% |
| Q3 2022 | 9.06% |
| Q2 2022 | -21.96% |
| Q1 2022 | -33.08% |
| Q4 2021 | -19.72% |
| Q3 2021 | 42.63% |
| Q2 2021 | -21.06% |
| Q1 2021 | -28.42% |
| Q4 2020 | -28.16% |
| Q3 2020 | -20.13% |
| Q2 2020 | 30.98% |
| Q1 2020 | -19.26% |
| Q4 2019 | -53.11% |
| Q3 2019 | 29.30% |
| Q2 2019 | -16.43% |
| Q1 2019 | 12.06% |
| Q4 2018 | -6.33% |
| Q3 2018 | -25.38% |
| Q2 2018 | 23.21% |
| Q1 2018 | -41.85% |
| Q4 2017 | 1.12% |
| Q3 2017 | -26.18% |
| Q2 2017 | 27.53% |
| Q1 2017 | -37.24% |
| Q4 2016 | -313.38% |
| Q3 2016 | 138.30% |
| Q2 2016 | 44.59% |
| Q1 2016 | 24.25% |
| Q4 2015 | -13.59% |